B 5626

Drug Profile

B 5626

Alternative Names: B5626; Neksol PM

Latest Information Update: 22 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Samyang Biopharmaceuticals Corporation
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Lung cancer

Most Recent Events

  • 31 Jul 2006 Clinical trials in Breast cancer in South Korea (Parenteral) before July 2006
  • 31 Jul 2006 Clinical trials in Lung cancer in South Korea (Parenteral) before July 2006
  • 31 Jul 2006 Launched for Breast cancer in South Korea (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top